Literature DB >> 9389515

Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma.

K H Lin1, X G Zhu, H C Hsu, S L Chen, H Y Shieh, S T Chen, P McPhie, S Y Cheng.   

Abstract

Complementary DNAs for two mutant thyroid hormone alpha1 receptors (TR alpha1) were isolated from hepatocellular carcinomas of two patients. Sequence analyses of the complementary DNAs showed a single Val390Ala and double Pro398Ser/Glu350Lys mutations in mutants H and L, respectively. We characterized their hormone-binding, DNA-binding, and dominant negative activities. Mutants H and L did not bind the hormone T3. Their DNA-binding activities were analyzed using three types of thyroid hormone response elements (TREs) in which the half-site binding motifs are arranged in an everted repeat (Lys), an inverted repeat (Pal), or a direct repeat separated by four nucleotides (DR4). Compared with wild-type TR alpha1 (w-TR alpha1), which bound these TREs with different homodimer/monomer ratios, binding of mutant L to the three TREs as homodimers was reduced by approximately 90%. However, binding of mutant H to these TREs was more complex. Although it bound normally to DR4 as homodimers, its binding to Lys as homodimers was reduced by approximately 80%. Surprisingly, its binding to Pal was markedly enhanced compared with w-TR alpha1. The binding of these two mutants to the three TREs as heterodimers with retinoid X receptors (RXR alpha and -beta) was not significantly affected. Consistent with the lack of T3-binding activity, both mutants had lost their trans-activation capacity. Mutants H and L exhibited dominant negative activity, but differed in their TRE dependency. The dominant negative potency of mutant H was in the rank order of Pal > DR4 > Lys, whereas no TRE dependency was observed for mutant L. The present study indicates that mutations of the TR alpha gene do occur in patients and that these novel TR alpha1 mutants provide a valuable tool to further understand the molecular basis of the dominant negative action of mutant TRs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389515     DOI: 10.1210/endo.138.12.5625

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

1.  Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation.

Authors:  L D Miller; K S Park; Q M Guo; N W Alkharouf; R L Malek; N H Lee; E T Liu; S Y Cheng
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

2.  Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

3.  Thyroid hormone receptor mutations found in renal clear cell carcinomas alter corepressor release and reveal helix 12 as key determinant of corepressor specificity.

Authors:  Meghan D Rosen; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2009-04-30

Review 4.  Thyroid hormones and their nuclear receptors: new players in intestinal epithelium stem cell biology?

Authors:  Maria Sirakov; Elsa Kress; Julien Nadjar; Michelina Plateroti
Journal:  Cell Mol Life Sci       Date:  2014-03-07       Impact factor: 9.261

Review 5.  Genetic features of thyroid hormone receptors.

Authors:  Maha Rebaï; Imen Kallel; Ahmed Rebaï
Journal:  J Genet       Date:  2012       Impact factor: 1.166

Review 6.  Nuclear receptor coregulators as a new paradigm for therapeutic targeting.

Authors:  Elaine Y Hsia; Michael L Goodson; June X Zou; Martin L Privalsky; Hong-Wu Chen
Journal:  Adv Drug Deliv Rev       Date:  2010-10-07       Impact factor: 15.470

7.  A conserved lysine in the thyroid hormone receptor-alpha1 DNA-binding domain, mutated in hepatocellular carcinoma, serves as a sensor for transcriptional regulation.

Authors:  Ivan H Chan; Martin L Privalsky
Journal:  Mol Cancer Res       Date:  2010-01-06       Impact factor: 5.852

Review 8.  Germline and somatic thyroid hormone receptor mutations in man.

Authors:  P M Yen; S Y Cheng
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

9.  Hypothyroidism enhances tumor invasiveness and metastasis development.

Authors:  Olaia Martínez-Iglesias; Susana García-Silva; Javier Regadera; Ana Aranda
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

10.  Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.